Bristol-myers Squibb Compnay

Flexus Biosciences, Inc.

Syngene International Limited

Weiwei Guo

Jay A Markwalder

Jay Patrick Powers

John E Macor

T G Murali Dhar

Saleem Ahmad

James Aaron Balog

John V Duncia

Douglas G Batt

Joseph Anthony Tino

David K Williams

Weifang Shan

Audris Huang

Emily Charlotte Cherney

Juan Carlos Jaen

Steven P Seitz

Hunter Paul Shunatona

Maureen Kay Reilly

Maksim Osipov

Mikhail Zibinsky

Hilary Plake Beck

James Ross Walker

Liping Zhang

Susheel Jethanand Nara

Saumya Roy

John T Hynes

Natesan Murugesan

Scott Hunter Watterson

Daniel S Gardner

Ramesh Kumar Sistla

Qingjie Liu

Khehyong Ngu

Andrew J Tebben

Srinivas Cheruku

Hua Gong

Srinivasan Thangathirupathy

Soodamani Thangavel

Nagalakshmi Pulicharla

Yadagiri Kanyaboina

Xiao Zhu

Myra Beaudoin Bertrand

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Immunoregulatory agents

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention. 

Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer

IDO inhibitors

The present application describes modulators of chemokine receptor activity of formula I or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

Spirocyclic compounds as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptor activity of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed. 

Growing community of inventors

Lawrenceville, NJ, United States of America

Weiwei Guo